NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 82 filers reported holding NGM BIOPHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 1.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $222,406 | -80.4% | 207,898 | -52.6% | 0.00% | – |
| Q2 2023 | $1,135,470 | -40.0% | 438,533 | -5.5% | 0.00% | -100.0% |
| Q1 2023 | $1,892,528 | +68769.3% | 463,898 | -15.3% | 0.00% | 0.0% |
| Q4 2022 | $2,748 | -100.0% | 547,865 | -30.5% | 0.00% | -75.0% |
| Q3 2022 | $10,303,000 | +24.3% | 787,808 | +21.8% | 0.00% | +33.3% |
| Q2 2022 | $8,292,000 | -2.8% | 646,718 | +15.6% | 0.00% | 0.0% |
| Q1 2022 | $8,531,000 | +11.1% | 559,339 | +29.0% | 0.00% | +50.0% |
| Q4 2021 | $7,679,000 | +51.2% | 433,607 | +79.4% | 0.00% | 0.0% |
| Q3 2021 | $5,080,000 | +101.9% | 241,721 | +89.5% | 0.00% | +100.0% |
| Q2 2021 | $2,516,000 | -40.2% | 127,557 | -12.2% | 0.00% | 0.0% |
| Q1 2021 | $4,209,000 | +95.8% | 145,264 | +104.8% | 0.00% | 0.0% |
| Q4 2020 | $2,150,000 | +178.9% | 70,932 | +46.5% | 0.00% | – |
| Q3 2020 | $771,000 | +245.7% | 48,432 | +328.0% | 0.00% | – |
| Q2 2020 | $223,000 | – | 11,316 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 15,396,116 | $303,611,000 | 42.97% |
| Ponoi II Management, LLC | 1,298,908 | $25,614,000 | 20.76% |
| Ponoi Management, LLC | 1,298,908 | $25,614,000 | 14.23% |
| Euclidean Capital LLC | 1,493,349 | $29,449,000 | 9.56% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $74,279,000 | 6.80% |
| Aquilo Capital Management, LLC | 1,194,237 | $23,550,000 | 6.12% |
| Greenspring Associates, LLC | 1,573,357 | $31,027,000 | 2.10% |
| Octagon Capital Advisors LP | 200,000 | $3,944,000 | 0.82% |
| Redmile Group, LLC | 2,792,448 | $55,067,000 | 0.82% |
| BVF INC/IL | 955,000 | $18,833,000 | 0.71% |